Report cover image

Antiviral Drugs Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

Publisher Persistence Research & Consultancy Services
Published Nov 11, 2025
Length 188 Pages
SKU # PERR20602059

Description

Persistence Market Research has recently published an in-depth analysis of the global antiviral drugs market, offering a detailed evaluation of key market dynamics, including drivers, trends, opportunities, and challenges. The report provides exclusive data and statistical insights that highlight the expected growth trajectory of the antiviral drugs market from 2025 to 2032.

Key Insights:
  • Antiviral Drugs Market Size (2025E): US$ 75.4 Bn
  • Projected Market Value (2032F): US$ 207.9 Bn
Global Market Growth Rate (CAGR 2025 to 2032): 15.60%



Antiviral Drugs Market - Report Scope

Antiviral drugs are pharmaceutical agents designed to treat viral infections by inhibiting virus replication within the host. These drugs are essential in managing diseases such as influenza, HIV, hepatitis, and COVID-19. The increasing prevalence of viral infections, coupled with advancements in drug development, has significantly driven the demand for antiviral therapies. The market caters to hospitals, clinics, research institutions, and pharmaceutical companies, offering a wide range of treatment options. Additionally, the rising adoption of combination therapies and personalized medicine further propels market growth.

Market Growth Drivers

The global antiviral drugs market is expanding due to several key factors, including the rising incidence of viral diseases worldwide. The increasing burden of chronic viral infections such as HIV and hepatitis B & C is fueling demand for effective antiviral treatments. Moreover, the COVID-19 pandemic highlighted the urgent need for antiviral drug development, leading to accelerated research and innovation. Advancements in antiviral drug formulations, including long-acting injectables and nanotechnology-based drug delivery systems, are improving treatment efficacy and patient compliance. Furthermore, government initiatives and funding for antiviral drug research, along with strategic collaborations between pharmaceutical companies, are supporting market expansion.

Market Restraints

Despite its promising growth, the antiviral drugs market faces challenges such as high research and development (R&D) costs and lengthy regulatory approval processes. The emergence of drug-resistant viral strains poses a significant hurdle, necessitating continuous drug modifications and new treatment strategies. Additionally, limited accessibility and affordability of antiviral drugs in low- and middle-income countries restrict market penetration. Side effects and adverse reactions associated with antiviral medications also impact patient adherence and treatment outcomes.

Market Opportunities

The antiviral drugs market presents significant growth opportunities driven by ongoing advancements in biotechnology and drug discovery. The development of broad-spectrum antiviral drugs capable of targeting multiple viruses offers potential for market expansion. Additionally, the increasing adoption of artificial intelligence (AI) and machine learning in drug discovery is accelerating the identification of novel antiviral compounds. The integration of antiviral drugs with immunotherapies and monoclonal antibodies is expected to enhance treatment effectiveness. Expanding healthcare infrastructure in emerging economies, coupled with rising investments in infectious disease research, will further drive market growth.

Key Questions Answered in the Report:
  • What are the primary factors driving the growth of the antiviral drugs market globally?
  • How are regulatory policies influencing the development and approval of antiviral medications?
  • What are the emerging trends and technological advancements shaping the market?
  • Who are the key players contributing to the market, and what strategies are they employing to maintain their competitive edge?
  • What are the future growth opportunities and investment prospects in the global antiviral drugs market?
Competitive Intelligence and Business Strategy

Leading players in the global antiviral drugs market, including Gilead Sciences, GlaxoSmithKline, and Merck & Co., focus on continuous innovation, strategic partnerships, and mergers & acquisitions to strengthen their market position. These companies invest heavily in R&D to develop next-generation antiviral therapies with enhanced efficacy and safety profiles. Collaborations with government agencies, research institutes, and biotech firms are accelerating drug discovery and development processes. Additionally, increased efforts in expanding global distribution networks and improving access to antiviral drugs in underserved regions are expected to drive long-term market growth.

Key Companies Profiled:
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • AbbVie
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Aurobindo Pharma
  • Dr. Reddy’s Laboratories Ltd.
Antiviral Drugs Market Segmentation

By Drug Class
  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Others
By Type
  • Branded
  • Generics
By Application
  • HIV
  • Hepatitis
  • Herpes
  • Influenza
  • Others
By Region
  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Latin America
  • The Middle East & Africa


Please Note: It will take 5 business days to complete the report upon order confirmation.

Table of Contents

188 Pages
1. Executive Summary
1.1. Global Antiviral Drugs Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Product Adoption Analysis
3.3. Key Promotional Strategies by Manufacturer
3.4. Value Chain Analysis
3.5. Key Deals and Mergers
3.6. PESTLE Analysis
3.7. Porter’s Five Force Analysis
4. Global Antiviral Drugs Outlook, 2019-2032
4.1. Key Highlights
4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
4.3. Global Antiviral Drugs Market Outlook: Drug Class
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2024
4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025-2032
4.3.3.1. DNA Polymerase Inhibitors
4.3.3.2. Reverse Transcriptase Inhibitors
4.3.3.3. Protease Inhibitors
4.3.3.4. Neuraminidase Inhibitors
4.3.3.5. Others
4.3.4. Market Attractiveness Analysis: Drug Class
4.4. Global Antiviral Drugs Market Outlook: Type
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Bn) Analysis, By Type, 2019-2024
4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2025-2032
4.4.3.1. Branded
4.4.3.2. Generics
4.4.4. Market Attractiveness Analysis: Type
4.5. Global Antiviral Drugs Market Outlook: Application
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2024
4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
4.5.3.1. HIV
4.5.3.2. Hepatitis
4.5.3.3. Herpes
4.5.3.4. Influenza
4.5.3.5. Others
4.5.4. Market Attractiveness Analysis: Application
5. Global Antiviral Drugs Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Antiviral Drugs Outlook, 2019-2032
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
6.2.1. By Country
6.2.2. By Drug Class
6.2.3. By Type
6.2.4. By Application
6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025-2032
6.4.1. DNA Polymerase Inhibitors
6.4.2. Reverse Transcriptase Inhibitors
6.4.3. Protease Inhibitors
6.4.4. Neuraminidase Inhibitors
6.4.5. Others
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2025-2032
6.5.1. Branded
6.5.2. Generics
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
6.6.1. HIV
6.6.2. Hepatitis
6.6.3. Herpes
6.6.4. Influenza
6.6.5. Others
6.7. Market Attractiveness Analysis
7. Europe Antiviral Drugs Outlook, 2019-2032
7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
7.2.1. By Country
7.2.2. By Drug Class
7.2.3. By Type
7.2.4. By Application
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025-2032
7.4.1. DNA Polymerase Inhibitors
7.4.2. Reverse Transcriptase Inhibitors
7.4.3. Protease Inhibitors
7.4.4. Neuraminidase Inhibitors
7.4.5. Others
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2025-2032
7.5.1. Branded
7.5.2. Generics
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
7.6.1. HIV
7.6.2. Hepatitis
7.6.3. Herpes
7.6.4. Influenza
7.6.5. Others
7.7. Market Attractiveness Analysis
8. East Asia Antiviral Drugs Outlook, 2019-2032
8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
8.2.1. By Country
8.2.2. By Drug Class
8.2.3. By Type
8.2.4. By Application
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025-2032
8.4.1. DNA Polymerase Inhibitors
8.4.2. Reverse Transcriptase Inhibitors
8.4.3. Protease Inhibitors
8.4.4. Neuraminidase Inhibitors
8.4.5. Others
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2025-2032
8.5.1. Branded
8.5.2. Generics
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
8.6.1. HIV
8.6.2. Hepatitis
8.6.3. Herpes
8.6.4. Influenza
8.6.5. Others
8.7. Market Attractiveness Analysis
9. South Asia & Oceania Antiviral Drugs Outlook, 2019-2032
9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
9.2.1. By Country
9.2.2. By Drug Class
9.2.3. By Type
9.2.4. By Application
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025-2032
9.4.1. DNA Polymerase Inhibitors
9.4.2. Reverse Transcriptase Inhibitors
9.4.3. Protease Inhibitors
9.4.4. Neuraminidase Inhibitors
9.4.5. Others
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2025-2032
9.5.1. Branded
9.5.2. Generics
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
9.6.1. HIV
9.6.2. Hepatitis
9.6.3. Herpes
9.6.4. Influenza
9.6.5. Others
9.7. Market Attractiveness Analysis
10. Latin America Antiviral Drugs Outlook, 2019-2032
10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
10.2.1. By Country
10.2.2. By Drug Class
10.2.3. By Type
10.2.4. By Application
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025-2032
10.4.1. DNA Polymerase Inhibitors
10.4.2. Reverse Transcriptase Inhibitors
10.4.3. Protease Inhibitors
10.4.4. Neuraminidase Inhibitors
10.4.5. Others
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2025-2032
10.5.1. Branded
10.5.2. Generics
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
10.6.1. HIV
10.6.2. Hepatitis
10.6.3. Herpes
10.6.4. Influenza
10.6.5. Others
10.7. Market Attractiveness Analysis
11. Middle East & Africa Antiviral Drugs Outlook, 2019-2032
11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
11.2.1. By Country
11.2.2. By Drug Class
11.2.3. By Type
11.2.4. By Application
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025-2032
11.4.1. DNA Polymerase Inhibitors
11.4.2. Reverse Transcriptase Inhibitors
11.4.3. Protease Inhibitors
11.4.4. Neuraminidase Inhibitors
11.4.5. Others
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2025-2032
11.5.1. Branded
11.5.2. Generics
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
11.6.1. HIV
11.6.2. Hepatitis
11.6.3. Herpes
11.6.4. Influenza
11.6.5. Others
11.7. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2025
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. F. Hoffmann-La Roche Ltd.
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. GlaxoSmithKline plc
12.3.3. AbbVie
12.3.4. Merck & Co., Inc.
12.3.5. Johnson & Johnson Services, Inc.
12.3.6. Bristol-Myers Squibb Company
12.3.7. Cipla Inc.
12.3.8. Aurobindo Pharma
12.3.9. Dr. Reddy’s Laboratories Ltd.
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us